← All trials
NCT07234695
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Jul 31, 2028
- First posted
- Nov 18, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BarcelonaLead sponsor
- University Hospital Virgen de las NievesCollaborator
- Universidad Autonoma de MadridCollaborator
- University of CantabriaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.